Skip to content

Management of Patients With Type 2 Diabetes and Hypertension Using Mobile Health Care System

Efficacy of Mobile Health Care System in Patients With Type 2 Diabets and Hypertension

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00489879
Enrollment
140
Registered
2007-06-21
Start date
2007-07-31
Completion date
2007-10-31
Last updated
2008-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Hypertension, Obesity

Keywords

Mobile Health Units, Chronic Disease

Brief summary

The purpose of this study is to determine whether cellular phone based health care system is effective in the treatment of diabetes and hypertension.

Detailed description

Diabetes care is facilitated by a patient's being engaged in a self-management program with the advice and counsel of physicians, but many diabetic patients can not receive the continous monitoing and advice from his physician in their every day life. It is very difficult to keep up life style modification in their real life. Few studies have examined the effects of cellular phone based intervention that provide an interactive component daily. Our goal is to test the hypothesis that diabetes and hypertension management using cellular phone based health care system would result in significant improvement of blood glucose and blood pressure level.

Interventions

DEVICEMobile Health Care System (DrUB)

Sponsors

Korea University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* type II diabetes using only oral hypoglycemic agents * 7% \< HbA1c \< 10% * systolic blood pressure \> 130 or diastolic blood pressure \> 80 * BMI \> 23 * 20 \< age \< 75

Exclusion criteria

* type I diabetes or type II diabtes using insulin treatment * liver, renal or heart disease * recent change (within 1 month) in the type or dosage of anti-diabetic agent, anti-hypertensive medication

Design outcomes

Primary

MeasureTime frame
HbA1c, fasting blood glucose level, Weight change, Blood pressure level in the morning, lipid profilesbaseline, 3months later

Secondary

MeasureTime frame
exercise time during one week, self reported change in dietary habit, fat consumption ratiobaseline, 3months later

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026